Syndax Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Syndax Pharmaceuticals, Inc. (SNDX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 3.98 million shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-02-26
- Syndax Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 3.98M shares, a 37.75% increase from fiscal 2024.
- Syndax Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 2.89M shares, a 24.04% decline from fiscal 2023.
- Syndax Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 3.80M shares, a 25.82% increase from fiscal 2022.
- Syndax Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 3.02M shares, a 89.35% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|
| 2025-12-31 | 3.98M shares 10-K · filed 2026-02-26 |
| 2024-12-31 | 2.89M shares 10-K · filed 2025-03-03 |
| 2023-12-31 | 3.80M shares 10-K · filed 2024-02-27 |
| 2022-12-31 | 3.02M shares 10-K · filed 2023-02-28 |
| 2021-12-31 | 1.60M shares 10-K · filed 2022-03-01 |
| 2020-12-31 | 1.64M shares 10-K · filed 2021-03-12 |
| 2019-12-31 | 1.96M shares 10-K · filed 2020-03-05 |
| 2018-12-31 | 1.05M shares 10-K · filed 2019-03-07 |
| 2017-12-31 | 967.49K shares 10-K · filed 2018-03-08 |
| 2016-12-31 | 478.53K shares 10-K · filed 2017-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |